急诊腹腔镜治疗出血性宫外孕202例临床分析

目的探讨急诊腹腔镜治疗出血性宫外孕的可能性、优越性。方法回顾分析1998年8月~2005年10月急诊腹腔镜出血性宫外孕402例,随机分为腹腔镜组202例,开腹组200例。比较两组手术时间、并发症、术后病率、术后输卵管通畅情况。结果腹腔镜比开腹手术住院时间短、术后恢复快、并发症少、术后病率少。手术时间,腹腔镜组(1998年8月~2001年12月)比开腹手术组长,(2002年1月~2005年10月)短于开腹组,结论腹腔镜手术应用于急腹症出血性宫外孕,当休克早期,在抗休克的同时行腹腔镜手术较安全、有效,病人术后恢复快、不增加并发症,更适应有生育要求患者。     

肠腔静脉人工血管C型分流术的远期疗效观察

目的 探讨肠腔静脉C型分流术治疗食管胃底静脉曲张破裂出血的远期疗效。方法 对成阳市中心医院肝胆外科1992年以来施行的36例肠腔静脉C型分流术的临床资料进行总结分析。结果 36例患者术后门静脉压平均下降1．51kPa，胃镜检查食管静脉曲张均有明显减轻或消失。术后再出血率5．6％，肝性脑病发生率8_3％，术后1年、3年、5年及10年的生存率分别为97．2％、93．3％、89．3％及66．7％。结论肠腔静脉C型分流术手术适应证广，操作简单，近、远期疗效满意，适于推广。     

Atypical Ph negative chronic myeloid leukaemia presenting as sudden profound deafness.

A patient with atypical Ph negative chronic myeloid leukaemia presented with the sudden onset of profound deafness. He survived only eight months. Detailed histological investigation performed at necropsy showed loss of ganglion cells and afferent nerve fibres in the cochlea and vestibule associated with extensive fibrosis and new bone formation in the labyrinthine spaces. Both leucophoresis and high dose chemotherapy capable of rapid cytoreduction are recommended in patients with chronic myeloid leukaemia with profound hearing loss, as conventional chemotherapy is rarely followed by recovery.     

重组Rab8截短体蛋白的原核表达、纯化和抗体制备

目的 获得Rab8纯化蛋白,制备多克隆抗体,为深入研究Rab8在病毒感染宿主细胞过程中的作用奠定基础.方法 首先从HepG2细胞中克隆Rab基因,然后从Rab8质粒中亚克隆Rab8 C端编码122个氨基酸的基因片段,构建Rab8与6His的融合蛋白原核表达质粒.原核表达与蛋白纯化后,免疫动物,制备Rab8多克隆抗体.采用ELISA法检测其效价.Western检验抗体特异性,间接免疫荧光染色法验证其免疫组化特性.结果 克隆了人Rab8编码基因,构建了表达Rab8 C端编码122个氨基酸的原核表达质粒pQE31-Rab8-122,经过大肠杆菌表达、镍亲和层析柱纯化,获得相对分子量约15 000的融合蛋白,免疫Balb/c小鼠后收获抗血清.ELISA显示抗体效价达1/20 000.Western blot和免疫荧光染色结果显示此多克隆抗体能够与原核表达的Rab8蛋白发生特异性反应,并能够识别HepG2细胞中内源性Rab8蛋白.结论 本研究获得原核表达的Rab8纯化蛋白,成功的制备了Rab8多克隆抗体,为进一步研究Rab8参与病毒感染宿主细胞提供了重要的实验材料.     

生长抑制因子1基因核定位序列-绿荧光蛋白融合表达载体的构建及表达

目的构建p33^ING1b核定位序列（nuclear locating sequence，NLS）-绿荧光蛋白融合表达载体，将其转染到人胚肺纤维母细胞系MRC-5，建立稳定表达该融合蛋白的细胞模型。方法应用逆转录PCR获得p33^ING1b的NLS序列，然后将NLS序列插入绿荧光蛋白融合表达载体pEGFP-C1的多克隆位点，构建pEGFP-C1-NLS-绿荧光蛋白融合表达载体，再用此载体转染MRC-5细胞系，观察活细胞绿荧光蛋白的亚细胞定位。结果成功构建了pEGFP-C1-NLS-绿荧光蛋白融合表达载体，由该载体表达的绿荧光蛋白-NLS肽段融合蛋白产生的绿色荧光信号全部定位于胞核部位，而空载体转染的细胞表达的绿色荧光蛋白，绿色荧光信号定位于细胞浆中。结论在活细胞内，生理情况下p33^ING1b完全定位于细胞核，并且在其亚细胞定位的转运过程中，NLS肽段起着决定性作用。     

四川省蚋亚属一新种（双翅目：蚋科）

本文记述四川省峨眉山蚋属Simulium蚋亚属Simulium一新种，以中国科学院院士胡经甫命名为经甫蚋S．（S．）jinfful sp．nov．该蚋与S．（S．）himalayense Purl，1930，S．（S．）taiwanicum Takaoka，1979．S．（S．）shanxlense Cai and An，2003，S．（S．）immortalls Cai and An，2003，S．（S．）chamlongi Takaoka and Suzuki，1984相似，但是，雌虫的生殖叉突具内突和外突，肛上板椭圆形，前腿基节、转节、股节棕黄色；生殖腹板板体短，其长约为顶端宽度的0．8倍，与上述蚋种明显不同。模式标本保存在北京军事医学科学院医学昆虫标本馆。     

Lassa fever. Effective therapy with ribavirin

In a study of Lassa fever in Sierra Leone, West Africa, we identified two variables associated with a high risk of death, and we evaluated the efficacy of ribavirin and Lassa virus-convalescent plasma for the treatment of Lassa fever. A serum aspartate aminotransferase level greater than or equal to 150 IU per liter at the time of hospital admission was associated with a case-fatality rate of 55 percent (33 of 60). Patients with the same risk factor who were treated for 10 days with intravenous ribavirin, begun within the first 6 days after the onset of fever, had a case-fatality rate of 5 percent (1 of 20) (P = 0.0002 by Fisher's exact test). Patients whose treatment began seven or more days after the onset of fever had a case-fatality rate of 26 percent (11 of 43) (P = 0.01). Viremia with levels greater than or equal to 10(3.6) TCID50 per milliliter on admission was associated with a case-fatality rate of 76 percent (35 of 46). Patients with this risk factor who were treated with intravenous ribavirin within the first six days after onset of fever had a case-fatality rate of 9 percent (1 of 11) (P = 0.006), whereas those treated after seven days or more of illness had a fatality rate of 47 percent (9 of 19) (P = 0.035). Oral ribavirin was also effective in patients at high risk of death. Lassa-convalescent plasma did not significantly reduce mortality in any of the high-risk groups. We conclude that ribavirin is effective in the treatment of Lassa fever and that it should be used at any point in the illness, as well as for postexposure prophylaxis.     

Trophoblast apoptosis in human placenta at term as detected by expression of a cytokeratin 18 degradation product of caspase

CONTEXT: Apoptosis occurs in the normal placenta. The monoclonal antibody M30 is directed against a novel epitope of cytokeratin 18 (CK18) that is formed by caspase cleavage early in the apoptotic cascade, and this antibody may therefore be useful for evaluating trophoblast apoptosis. OBJECTIVE: We undertook the present study to evaluate the use of monoclonal antibody M30 to assess trophoblast apoptosis in placenta at term. METHODS: We stained paraffin-embedded placental tissues from 15 deliveries at term with M30. We compared positive M30 staining and CK18 staining (as detected by a monoclonal antibody directed against CK18) of trophoblasts in serial slides. We also compared apoptotic rates as detected by M30 and TUNEL (terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling) in 7 of the placentas. RESULTS: In fields of villous tissue, most M30-positive cells were CK18-positive syncytiotrophoblasts. Approximately half of M30-positive cells occurred as focal positive staining in the syncytial layer, and half occurred as abundant staining of syncytiotrophoblasts in areas with increased intervillous or perivillous fibrinoid. We found very few M30-positive cells in villous stroma. In decidual/basal plate tissues, most (two thirds) of the M30-positive cells were CK18-positive extravillous trophoblasts, whereas one third were syncytiotrophoblasts of anchoring villi. Since TUNEL detects apoptosis in both epithelial and nonepithelial cells, more cells were positively stained with TUNEL than with M30 in some tissue fields. However, our observations suggest that M30 was more sensitive than TUNEL in recognizing apoptotic trophoblasts and had less nonspecific staining than TUNEL. CONCLUSION: We recommend the use of monoclonal antibody M30 for apoptosis studies in placental tissues. This antibody is easy to handle, the staining obtained seems specific, and the nonspecific staining seems negligible.     

A second locus (GLC3B) for primary congenital glaucoma (Buphthalmos) maps to the 1p36 region

Primary congenital glaucoma (gene symbol: GLC3) is an ocular disorder that occurs for 0.01-0.04% of blind people. In the majority of familial cases reported so far, this condition is inherited as an autosomal recessive trait. We have recently used a group of 17 GLC3 families with a minimum of two affected offspring and consanguinity in most of the parental generation and mapped the first GLC3 locus (GLC3A) to the 2p21 region. Six families did not show any linkage to the GLC3A locus and thus provided evidence for genetic heterogeneity of this disorder. A total of eight families unlinked to the 2p21 region were used to search for the chromosomal location of the second GLC3 locus. Herein, we describe mapping of a new locus (designated GLC3B) for primary congenital glaucoma to the short arm of chromosome 1 (1p36.2-36.1) that is situated centromeric to the neuroblastoma and Charcot-Marie-Tooth type 2A (CMT2A) loci. A total of 17 DNA markers were genotyped from this region of chromosome 1. Four families showed no recombination with the two markers D1S2834 and D1S402 with a maximum lod score of 4.510 and 4.157 respectively. Pairwise and multipoint linkage analysis and inspection of the haplotypes revealed that the remaining four families are not linked to this part of chromosome 1, thus providing further evidence that at least one more locus for the autosomal recessive form of GLC3 must exist in the genome. Based on the recombination events, the overall linkage map of this region is: tel-D1S1192-D1S1635-D1S1193 - (D1S1597/-D1S489/D1S228)- [GLC3B/D1S2834/D1S402] - (D1S1176/D1S507/D1S407) - D1S2728-(MFAP2/D1S170) - D1S1368 - D1S436- D1S1592-cen.      

The diagnosis of major depression in renal dialysis patients

Controversy exists regarding the frequency of depression in renal dialysis patients. We have assessed an unselected sample of 99 dialysis patients using the Diagnostic Interview Schedule (DIS). A current Major Depressive Episode (MDE) was diagnosed in 8.1% of the sample, one-half of whom had a past history of MDE. An additional 12.1% had only a past history of depression. In contrast to patients with no affective disorder, characteristics of patients with a current MDE included the following: a history of previous MDE; female sex; duration of dialysis less than or equal to 24 months; a younger mean age; solitary living arrangements; and unemployment. The following DSM-III criteria distinguished patients with MDE from those with no affective disorder: depressed mood or loss of interest; feelings of worthlessness or excessive guilt; anorexia and weight loss; and slowed or mixed-up thoughts. DSM-III criteria that were common in the entire sample but not useful in distinguishing patients with MDE included loss of energy, insomnia, and decreased sexual interest. These results indicate that some DSM-III criteria are common in dialysis patients and therefore do not distinguish major depression, whereas other DSM-III criteria are more specific for MDE. Further, it is possible that the prevalence of MDE is greater in dialysis patients than in the general population.